News from Rhythm A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 26, 2017, 20:48 ET American Honda Honors Rhythm With Premier Partner Award

Rhythm - an Irvine-based digital marketing agency - was presented with American Honda's distinguished Premier Partner Award on Sept. 12, 2017 in a...


Aug 01, 2017, 08:00 ET Rhythm Expands Executive Leadership Team

Rhythm, a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for treatment of rare genetic...


Jun 27, 2017, 02:00 ET Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity

Rhythm and Camurus today announced positive initial results from an ongoing Phase 1A clinical trial evaluating the pharmacokinetics and...


May 17, 2017, 08:10 ET Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity

Rhythm today announced the expansion of the company's Phase 2 clinical trials of setmelanotide to the treatment of Bardet-Biedl syndrome (BBS)...


May 11, 2017, 08:00 ET Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity

Rhythm today announced that the U.S. Food and Drug Administration (FDA) has expanded a previously granted Breakthrough Therapy Designation (BTD)...


May 04, 2017, 08:00 ET Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Apr 11, 2017, 08:00 ET Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Feb 16, 2017, 08:31 ET Rhythm Announces Completion of $41 Million Mezzanine Financing

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Nov 04, 2016, 08:30 ET Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Sep 19, 2016, 09:00 ET FierceBiotech Names Rhythm as a "Fierce 15" Biotechnology Company of 2016

Rhythm announced today that it has been named to the annual FierceBiotech "Fierce 15," designating Rhythm as one of the top privately held...


Jul 27, 2016, 08:00 ET Rhythm Announces "The Genetic Obesity Project" to Expand Understanding of Rare Genetic Disorders of Obesity

 Rhythm today announced "The Genetic Obesity Project" to improve the medical and scientific understanding of severe life-threatening obesity...


Jul 20, 2016, 17:00 ET Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity

Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Jan 07, 2016, 08:45 ET Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

 Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies that result in life-threatening metabolic...


Jan 07, 2016, 08:45 ET Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Rhythm announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for setmelanotide (RM-493), the...


Jan 05, 2016, 08:00 ET Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide

 Rhythm and Camurus announced today a license agreement for the use of Camurus' drug delivery technology, FluidCrystal®, to formulate...


Dec 16, 2015, 08:00 ET Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors

 Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic metabolic disorders, announced today that the company has...


Nov 06, 2015, 08:42 ET Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity

Rhythm Pharmaceuticals, Inc. announced today the presentation of results from an evaluation of cardiovascular safety in three Phase 1b/2a clinical...


Nov 06, 2015, 08:40 ET Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity

 Rhythm Pharmaceuticals, Inc. announced today the results from a proof-of-concept, Phase 1b clinical trial assessing the safety and efficacy of...


Dec 11, 2014, 08:00 ET Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer

 Rhythm announced today the appointment of Fred T. Fiedorek, MD, as Chief Medical Officer. In this position, Dr. Fiedorek will oversee clinical...


Oct 24, 2014, 08:00 ET Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation

Rhythm announced today the presentation of results from a Phase 2a clinical trial assessing the safety and efficacy of relamorelin (RM-131) in 48...


Oct 22, 2014, 08:30 ET Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced that...


Jun 23, 2014, 08:00 ET Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study

 Rhythm announced today the presentation of results from a clinical trial that evaluated the effect of RM-493, the company's novel melanocortin...


May 06, 2014, 11:02 ET Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study

Rhythm announced today the presentation of pharmacodynamic results from a Phase 2 clinical trial with relamorelin (RM-131) for the treatment of...


May 06, 2014, 11:00 ET Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

 Rhythm announced today the presentation of results from a Phase 2 clinical trial assessing the safety and efficacy of relamorelin (RM-131) in...


Sep 24, 2013, 08:00 ET Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant

 Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor...